We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Sanofi | EU:SAN | Euronext | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.68 | 0.77% | 88.85 | 88.00 | 89.00 | 89.17 | 88.03 | 88.40 | 1,062,952 | 02:00:52 |
From Apr 2021 to Apr 2024
By Cecilia Butini
Sanofi SA said Monday that its infant respiratory-virus drug Nirsevimab met its primary endpoint in a Phase 3 trial.
The French pharmaceutical company said the drug, which was being investigated as a single-dose immunization against respiratory syncytial virus, provided statistically significant reductions in lower respiratory tract infections in infants.
The drug has been developed in partnership with AstraZeneca PLC. Regulatory submissions are expected to begin in 2022, Sanofi said.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
April 26, 2021 02:28 ET (06:28 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
